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Amplification of the c-myc oncogene has been described in
both moderately well differentiated and poorly differentiated
gastric adenocarcinoma (Shibuya et al., 1985; Koda et al.,
1985). The greatest levels of c-myc mRNA were observed in
the poorly differentiated tumours (Shibuya et al., 1985). It
would seem likely therefore that detectable levels of the gene
product p62c-mYc would be found in association with these
tumours. In this study the presence of p62c-mYc has been
evaluated in a series of archival specimens of gastric cancer
by an immunohistochemical assay.
Tissue sections (6pm) were cut from formalin fixed
paraffin embedded blocks of 93 specimens of gastric cancer.
The tissues were treated by a streptavidin-biotin immuno-
peroxidase technique. A monoclonal antibody Mycl-6E10
raised by peptide fragment immunisation (Evan et al., 1985)
was used to detect the p62c-mYc product. This antibody has
been shown to bind to colonic adenoma with dysplasia and
well differentiated adenocarcinomas (Stewart et al., 1985).
Recently, close correlation between c-myc mRNA copy
number as determined by Northern blotting and abundance
of p62C-mYc has been demonstrated (Sikora et al., 1987).
The results are shown in Table I. Less than 40% of the
tumours contained cells which stained positively. In those
tumours with positive staining, there was no correlation with
the degree of differentiation. All tumours were also classified
according to the Lauren (1965) classification. There was a
tendency for the intestinal type tumours to stain more
frequently than the diffuse type.
Since a role in cell growth and differentiation has been
proposed for c-myc (Goyette et al., 1983; Evan & Hancock,
1985), this study also evaluated staining with Mycl-6E10 in
a range of gastric epithelial changes, some of which are
considered to have malignant potential. The surface
epithelium in histological sections of normal stomach, active
superficial gastritis with foveolar hyperplasia, chronic
superficial gastritis and atrophic gastritis both with and
without intestinal metaplasia were examined using the
streptavidin-biotin immunoperoxidase assay. Those sections
showing intestinal metaplasia were also stained for sulpho-
mucin using the high iron diamine technique in order to sub-
classify those in which type 2b metaplasia was present (Jass,
1980).
Table I p62cmYc staining of gastric carcinoma
Differentiation Total No. positive
Well 8 4 (50%)
Moderate 48 16 (33%)
Poor 37 15 (38%)
93 35 (38%)
Histological classification (Lauren) Total No. positive
Intestinal 50 20 (40%)
Diffuse 39 11 (28%)
Mixed 4 4 (100%)
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The results are presented in Table II. The principal site of
staining was cytoplasmic despite the apparent nuclear
location of p62c-mYc (Eisenman et al., 1985). Others have
reported similar results (Stewart et al., 1986) and have
suggested that processing of the tissues affects the cellular
location of the gene product.
Staining of surface epithelium was seen in all tissue types,
but was significantly more common in cases of gastritis than
in normal stomachs. This was particularly marked in
atrophic gastric mucosa showing intestinal metaplasia,
especially where this was of type 2b. No difference was
observed between active and quiescent chronic superficial
gastritis, suggesting that the stain is not simply
demonstrating proliferating epithelium (Table II).
The surface epithelium showed generalised staining in
many of the positive cases (Figure 1), but in a proportion
the staining was limited to the tips of the mucosal folds, with
no stain present within cells lining the gastric pits. Since
epithelium at this location is not usually considered to be
active, this finding was unexpected. This staining pattern was
particularly marked in those biopsies showing type 2b
intestinal metaplasia (Table II).
The interpretation of these findings requires careful con-
sideration. The pattern of staining in the benign and
malignant tissues suggests that potentially malignant tissues
Figure 1 Example of intestinalised epithelium showing strong
expression ofp62c-mYc.
Table II p62c-1Yc staining ofbenign gastric epithelia
Diffuse
surface Tip
Histology No. staining (%) staining (%)
Normal 13 3 (23.1) 1 (7.7)
Chronic superficial
gastritis 24 14 (58.3) 4 (16.7)
Active superficial
gastritis with
foveolar hyperplasia 26 13 (50.0) 6 (23.1)
Atrophic gastritis with
intestinal metaplasia 27 19 (70.4) 7 (25.9)
Atrophic gastritis with
type 2b metaplasia 11 11 (100.0) 8 (72.7)
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have higher levels of p62c-mYc. Once malignant change has
occurred, the levels fall. However such a hypothesis assumes
that the Mycl-6E10 antibody is specific only for p62cmYc.
Although this antibody binds to a 62kD protein identifiable
with the p62c-mYc product (Sikora et al., 1987), there may be
cross reactivity with other proteins containing the same
peptide sequence used for the initial immunisation.
The apparent differential staining observed in the benign
tissues poses further questions. Since c-myc has a postulated
role in cell proliferation and differentiation, the patterns of
staining observed could suggest that Mycl-6E10 is binding
to not only p62'mYc but also to a marker of cellular
proliferation. However the high proportion of specimens of
relatively inactive atrophic gastritis which stained may
suggest either that some other protein is being detected or
that the gene is expressed in cells prior to undergoing
metaplasia from gastric to intestinal type.
In order to determine whether abnormal amounts ofp62c-mYc
are present in these tissues, it would seem more appropriate
to evaluate the levels of c-myc mRNA. This study is
underway in our laboratory by in situ hybridisation and the
results should indicate the significance of c-myc in both
benign and malignant gastric epithelia.
Thanks to Prof. K. Sikora for the gift of the antibody Mycl-6E10.
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